A Randomized, Double-Blind Phase III Study to Demonstrate the Clinical Similarity of Biosimilar SCT630 to Reference Adalimumab in Chinese Patients with Moderate to Severe Plaque Psoriasis

SSRN Electronic Journal（2022）

引用 1|浏览4

暂无评分

摘要

•Phase III study was conducted in moderate-to-severity plaque psoriasis patients.•SCT630 and adalimumab showed equivalences in efficacy and similar safety.•Switching from adalimumab to SCT630 did not impact safety or efficacy.

查看译文

关键词

Adalimumab,SCT630,Plaque Psoriasis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要